Therefore, our present study together with previous findings suggest that CD133+ ovarian cancer cells are distinct from the CD133− population in terms of metastatic capability and CCL5 production, but the former can enhance the metastatic capacity of the latter. This evidence concerns the gene PROM1 and ovarian carcinoma.